B
Bruno Vincenzi
Researcher at Università Campus Bio-Medico
Publications - 528
Citations - 16675
Bruno Vincenzi is an academic researcher from Università Campus Bio-Medico. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 59, co-authored 480 publications receiving 14526 citations. Previous affiliations of Bruno Vincenzi include Sapienza University of Rome & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
Fotios Loupakis,Annamaria Ruzzo,Chiara Cremolini,Bruno Vincenzi,Lisa Salvatore,Daniele Santini,Gianluca Masi,I. Stasi,Emanuele Canestrari,Eliana Rulli,Irene Floriani,Katia Bencardino,N Galluccio,Vincenzo Catalano,Giuseppe Tonini,Mauro Magnani,Gabriella Fontanini,Fulvio Basolo,Alfredo Falcone,Francesco Graziano +19 more
TL;DR: Assessing KRAS codons 61/146 and BRAF V600E mutations might help optimising the selection of the candidate patients to receive anti-EGFR moAbs in metastatic colorectal cancer.
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
A. Ruzzo,Fotios Loupakis,Emanuele Canestrari,Chiara Cremolini,Bruno Vincenzi,Lisa Salvatore,Daniele Santini,Gianluca Masi,I. Stasi,Eliana Rulli,Irene Floriani,Katia Bencardino,N Galluccio,S. Demidio,Vincenzo Catalano,G. Tonini,Mauro Magnani,Alfredo Falcone,Francesco Graziano +18 more
TL;DR: In this paper, the role of KRAS codons 61 and 146 and BRAF V600E mutations in predicting resistance to cetuximab plus irinotecan in a cohort of CRC patients was investigated.
Journal Article
Zoledronic Acid Induces Significant and Long-Lasting Modifications of Circulating Angiogenic Factors in Cancer Patients
Daniele Santini,Bruno Vincenzi,Giordano Dicuonzo,Giuseppe Avvisati,Cristian Massacesi,Fabrizio Battistoni,Michele Gavasci,Laura Rocci,Maria Cristina Tirindelli,Vittorio Altomare,Massimo Tocchini,Maurizio Bonsignori,Giuseppe Tonini +12 more
TL;DR: This study confirms that zoledronic acid could have an in vivo antiangiogenic property through a significant and long-lasting reduction in serum VEGF levels.
Journal Article
Pamidronate Induces Modifications of Circulating Angiogenetic Factors in Cancer Patients
Daniele Santini,Bruno Vincenzi,Giuseppe Avvisati,Giordano Dicuonzo,Fabrizio Battistoni,Michele Gavasci,Alfredo Salerno,Vincenzo Denaro,Giuseppe Tonini +8 more
TL;DR: It is confirmed that pamidronate could have antiangiogenic properties through a significant and lasting decrease of VEGF serum levels, which is one of the possible mechanisms of anticancer activity attributed to bisphosphonates.